Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Risankizumab
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[4] 37, 96, 97, 271 💬
2Risankizumab (Genetical Recombination)
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 97 💬
3Risankizumab 10 mg/ml
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
4Risankizumab 180 mg SC
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
5Risankizumab 600 mg IV
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
6Risankizumab 90 mg/ml
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
7Risankizumab IV
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬
8Risankizumab On-Body Injector (OBI)
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[1] 96 💬
9Risankizumab SC
(D11052)		[1] Risankizumab[1] Risankizumab (D11052) 💬 [1] IL23A 💬 [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬[2] 96, 97 💬